Holt et al. proposed that low muscle mass at the initiation of anti-TNF therapy for IBD was identified as a risk factor for a secondary loss of response to anti-TNF therapy while the average observational period was approximately 2 years and the surgery rate was not mentioned (31). The gene discussed is TNF; the disease is inflammatory bowel disease.